Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

General considerations of model-based meta-analysis

Li, Lujin and Ding, Junjie (2020) General considerations of model-based meta-analysis. Chinese Journal of Clinical Pharmacology and Therapeutics, 25 (11). pp. 1250-1267. ISSN 10092501

Abstract

With the increasing cost of drug development and clinical trials, it is of great value to make full use of all kinds of data to improve the efficiency of drug development and to provide valid information for medication guidelines. Model-based meta-analysis (MBMA) combines mathematical models with meta-analysis to integrate information from multiple sources (preclinical and clinical data, etc.) and multiple dimensions (targets/mechanisms, pharmacokinetics/pharmacodynamics, diseases/indications, populations, regimens, biomarkers/efficacy/safety, etc.), which not only provides decision-making for all key points of drug development, but also provides effective information for rational drug use and cost-effectiveness analysis. The classical meta-analysis requires high homogeneity of the data, while MBMA can combine and analyze the heterogeneous data of different doses, different time courses, and different populations through modeling, so as to quantify the dose-effect relationship, time-effect relationship, and the relevant impact factors, and thus the efficacy or safety features at the level of dose, time and covariable that have not been involved in previous studies. Although the modeling and simulation methods of MBMA are similar to population pharmacokinetics/pharmacodynamics (Pop PK/PD), compared with Pop PK/PD, the advantage of MBMA is that it can make full use of literature data, which not only improves the strength of evidence, but also can answer the questions that have not been proved or can not be answered by a single study. At present, MBMA has become one of the important methods in the strategy of model-informed drug development (MIDD). This paper will focus on the application value, data analysis plan, data acquisition and processing, data analysis and reporting of MBMA, in order to provide reference for the application of MBMA in drug development and clinical practice.

Item Type: Article
Keywords: Cost-effectiveness analysis Drug development Expert consensus Model-based meta-analysis Rational use of medicines
Date Deposited: 10 Feb 2021 00:45
Last Modified: 10 Feb 2021 00:45
URI: https://oak.novartis.com/id/eprint/43505

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.